BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...in venture rounds. Two have gone public: Beam Therapeutics Inc....
BioCentury | Sep 29, 2020
Finance

With $77M series B, condensates company Dewpoint aiming for proof of concept

...next stage.”Dewpoint also named Giuseppe Ciaramella to its board. Ciaramella is president and CSO of Beam Therapeutics Inc....
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...assistant professor of bioengineering at the University of California San Diego.Behind its DNA editing programs, Beam Therapeutics Inc....
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...on multiple reports that did not cite sources saying the company is considering merging with Beam Therapeutics Inc....
...bacteria and sensitize them to antibiotics. Paul Bonanos, Associate Editor BioCentury Staff EDIT-101, lca10, AGN-151587 Editas Medicine Inc. AbbVie Inc. Allergan plc Beam Therapeutics Inc. Tangen...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

...New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM...
...protein Danielle Golovin, Staff Writer Chinese Academy of Sciences Agency for Science Technology and Research Massachusetts General Hospital Harvard Medical School Beam Therapeutics Inc. IBM Institute...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...2018. Two others, precision cancer company Black Diamond Therapeutics Inc. (NASDAQ:BDTX) and gene editing play Beam Therapeutics Inc....
BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

...editing pioneer, is a co-founder of CRISPR and base editing companies Editas Medicine Inc. (NASDAQ:EDIT), Beam Therapeutics Inc....
...NADH dehydrogenase subunit 4 Danielle Kopke, Staff Writer Broad Institute of MIT and Harvard University of Washington Editas Medicine Inc. Beam Therapeutics Inc. NADH...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

...in immune suppression that aids in tumor growth. Beam reports base editing proof of concept Beam Therapeutics Inc....
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...and the COVID-19 (2019-nCoV) coronavirus. The rest, including PPD, have posted double-digit gains since pricing: Beam Therapeutics Inc....
Items per page:
1 - 10 of 17
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...in venture rounds. Two have gone public: Beam Therapeutics Inc....
BioCentury | Sep 29, 2020
Finance

With $77M series B, condensates company Dewpoint aiming for proof of concept

...next stage.”Dewpoint also named Giuseppe Ciaramella to its board. Ciaramella is president and CSO of Beam Therapeutics Inc....
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...assistant professor of bioengineering at the University of California San Diego.Behind its DNA editing programs, Beam Therapeutics Inc....
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...on multiple reports that did not cite sources saying the company is considering merging with Beam Therapeutics Inc....
...bacteria and sensitize them to antibiotics. Paul Bonanos, Associate Editor BioCentury Staff EDIT-101, lca10, AGN-151587 Editas Medicine Inc. AbbVie Inc. Allergan plc Beam Therapeutics Inc. Tangen...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

...New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM...
...protein Danielle Golovin, Staff Writer Chinese Academy of Sciences Agency for Science Technology and Research Massachusetts General Hospital Harvard Medical School Beam Therapeutics Inc. IBM Institute...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...2018. Two others, precision cancer company Black Diamond Therapeutics Inc. (NASDAQ:BDTX) and gene editing play Beam Therapeutics Inc....
BioCentury | Jul 10, 2020
Tools & Techniques

Precise base editing of mitochondrial DNA

...editing pioneer, is a co-founder of CRISPR and base editing companies Editas Medicine Inc. (NASDAQ:EDIT), Beam Therapeutics Inc....
...NADH dehydrogenase subunit 4 Danielle Kopke, Staff Writer Broad Institute of MIT and Harvard University of Washington Editas Medicine Inc. Beam Therapeutics Inc. NADH...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

...in immune suppression that aids in tumor growth. Beam reports base editing proof of concept Beam Therapeutics Inc....
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...and the COVID-19 (2019-nCoV) coronavirus. The rest, including PPD, have posted double-digit gains since pricing: Beam Therapeutics Inc....
Items per page:
1 - 10 of 17